← Back to patent-cliff list
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical)
Tier C — Watch / tradeLevodopa/Carbidopa controlled release tablets(WD Pharmaceutical)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DDC, DRDs
Indications (approved)：Parkinsonism, Parkinson's disease
Regional status
US
-
EU
-
China
Phase II
2021-11-25
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical)?
Approved indications include: Parkinsonism, Parkinson's disease.
When does the Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) patent expire?
No public expiry year is available for Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06